- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06820463
Een studie om de bijwerkingen en werkzaamheid van intraveneus (iv) van Telisotuzumab adizutecan te evalueren in combinatie met IV oxaliplatine, fluorouracil, foliniczuur/leucovorine, bevacizumab, panitumab bij volwassen deelnemers met metastale kanker met metastale kanker met metastic (AndroMETa-CRC)
Een fase 2, open-label, gerandomiseerde, master protocolstudie om de veiligheid en werkzaamheid van meerdere behandelingscombinaties te evalueren met Telisotuzumab adizutecan bij personen met metastatische colorectale kanker
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab.
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: ABBVIE CALL CENTER
- Telefoonnummer: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Studie Locaties
-
-
New South Wales
-
Sydney, New South Wales, Australië, 2109
- Werving
- Macquarie University /ID# 271514
-
-
Queensland
-
South Brisbane, Queensland, Australië, 4101
- Werving
- Mater Misericordiae /ID# 270694
-
Contact:
- Site Coordinator
- Telefoonnummer: +61731632341
-
-
South Australia
-
Woodville South, South Australia, Australië, 5011
- Werving
- The Queen Elizabeth Hospital /ID# 270693
-
-
Victoria
-
Heidelberg, Victoria, Australië, 3084
- Werving
- Austin Health /ID# 270692
-
-
Western Australia
-
Nedlands, Western Australia, Australië, 6009
- Werving
- One Clinical Research /ID# 270695
-
-
-
-
-
São Paulo, Brazilië, 04014-002
- Werving
- Nucleo De Pesquisa Clinica Da Rede Sao Camilo /ID# 272311
-
São Paulo, Brazilië, 01401-002
- Werving
- Instituto D Or De Pesquisa E Ensino - Regional Sao Paulo /ID# 270546
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazilië, 41253-190
- Werving
- Hospital Sao Rafael /ID# 271681
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brazilië, 98700-000
- Werving
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 270147
-
-
São Paulo
-
Barretos, São Paulo, Brazilië, 14784-400
- Werving
- Hospital De Amor /ID# 271874
-
São José do Rio Preto, São Paulo, Brazilië, 15090-000
- Werving
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 271651
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Werving
- Arthur J.E Child Comprehensive Cancer Centre /ID# 269809
-
Edmonton, Alberta, Canada, T6G 1Z2
- Werving
- Cross Cancer Institute. /ID# 272711
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Werving
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270680
-
Toronto, Ontario, Canada, M5G 2M9
- Werving
- Princess Margaret Cancer Centre /ID# 268715
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- Werving
- Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 271368
-
-
-
-
-
Paris, Frankrijk, 75015
- Werving
- Hopital Europeen Georges Pompidou /ID# 270224
-
-
Hauts-de-France
-
Lille, Hauts-de-France, Frankrijk, 59037
- Werving
- Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez /ID# 270222
-
-
New Aquitaine
-
Poitiers, New Aquitaine, Frankrijk, 86021
- Werving
- Centre Hospitalier Universitaire de Poitiers /ID# 270225
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, Frankrijk, 44000
- Werving
- Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 270221
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Frankrijk, 75013
- Werving
- Hopital Pitie Salpetriere /ID# 270220
-
-
-
-
-
Thessaloniki, Griekenland, 54639
- Werving
- Theagenio Cancer Hospital /ID# 269640
-
-
Attica
-
Chaïdári, Attica, Griekenland, 12462
- Werving
- University General Hospital Attikon /ID# 268555
-
Nea Kifissia, Attica, Griekenland, 14564
- Werving
- General Oncology Hospital of Kifisia Agioi Anargyroi /ID# 268762
-
Piraeus, Attica, Griekenland, 18547
- Werving
- Metropolitan Hospital /ID# 269636
-
-
Thessaloniki
-
Panórama, Thessaloniki, Griekenland, 55236
- Werving
- St. Luke's Hospital /ID# 269963
-
-
-
-
-
Haifa, Israël, 3109601
- Werving
- Rambam Health Care Campus- Haifa /ID# 268006
-
Jerusalem, Israël, 9103102
- Werving
- Shaare Zedek Medical Center /ID# 268009
-
Jerusalem, Israël, 91120
- Werving
- Hadassah Medical Center-Hebrew University /ID# 268007
-
-
Central District
-
Petah Tikva, Central District, Israël, 4941492
- Werving
- Rabin Medical Center. /ID# 268008
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, Israël, 6423906
- Werving
- Tel Aviv Sourasky Medical Center /ID# 268010
-
-
-
-
Milano
-
Milan, Milano, Italië, 20162
- Werving
- ASST Grande Ospedale Metropolitano Niguarda /ID# 269142
-
Contact:
- Site Coordinator
- E-mail: ctu.oncologia@ospedaleniguarda.it
-
-
Napoli
-
Naples, Napoli, Italië, 80138
- Werving
- Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 269191
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Werving
- Aichi Cancer Center /ID# 270113
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- Werving
- National Cancer Center Hospital East /ID# 270114
-
-
Kanagawa
-
Kawasaki-shi, Kanagawa, Japan, 216-8511
- Werving
- St Marianna University School Of Medicine /ID# 270111
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
- Werving
- Tohoku University Hospital /ID# 270966
-
-
Tokyo
-
Chuo-Ku, Tokyo, Japan, 104-0045
- Werving
- National Cancer Center Hospital /ID# 270112
-
-
-
-
-
Salzburg, Oostenrijk, 5020
- Werving
- Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 268874
-
Vienna, Oostenrijk, 1090
- Werving
- Medizinische Universitaet Wien /ID# 268872
-
-
Styria
-
Graz, Styria, Oostenrijk, 8010
- Werving
- Medizinische Universitaet Graz /ID# 268876
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Werving
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268809
-
San Juan, Puerto Rico, 00917-5022
- Werving
- Puerto Rico Medical Research Center /ID# 268825
-
-
-
-
-
Barcelona, Spanje, 08035
- Werving
- Hospital Universitario Vall de Hebron /ID# 270191
-
Madrid, Spanje, 28027
- Werving
- Clinica Universidad de Navarra - Madrid /ID# 269754
-
Madrid, Spanje, 28046
- Werving
- Hospital Universitario La Paz /ID# 269730
-
Valencia, Spanje, 46010
- Werving
- Hospital Clinico Universitario de Valencia /ID# 269805
-
-
Cantabria
-
Santander, Cantabria, Spanje, 39008
- Werving
- Hospital Universitario Marques de Valdecilla /ID# 269732
-
-
Navarre
-
Pamplona, Navarre, Spanje, 31008
- Werving
- Clinica Universidad de Navarra - Pamplona /ID# 269753
-
-
-
-
-
Kaohsiung City, Taiwan, 807
- Werving
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 269724
-
Kaohsiung City, Taiwan, 833
- Werving
- Kaohsiung Chang Gung Memorial Hospital /ID# 269726
-
Tainan, Taiwan, 704
- Werving
- National Cheng Kung University Hospital /ID# 270835
-
Taipei, Taiwan, 112
- Werving
- Taipei Veterans General Hospital /ID# 269718
-
Taipei, Taiwan, 100
- Werving
- National Taiwan University Hospital /ID# 269717
-
Taoyuan City, Taiwan, 333
- Werving
- Linkou Chang Gung Memorial Hospital /ID# 269725
-
-
-
-
-
Brno, Tsjechië, 656 53
- Werving
- Masarykuv onkologicky ustav v Brne /ID# 268779
-
Hradec Králové, Tsjechië, 500 05
- Werving
- Fakultni nemocnice Hradec Kralove - Sokolska /ID# 268773
-
-
Praha 17
-
Prague, Praha 17, Tsjechië, 128 00
- Werving
- Vseobecna Fakultni nemocnice v Praze /ID# 268775
-
-
Praha 5
-
Prague, Praha 5, Tsjechië, 150 06
- Werving
- Fakultni nemocnice Motol a Homolka /ID# 268776
-
-
Praha, Hlavni Mesto
-
Prague, Praha, Hlavni Mesto, Tsjechië, 140 59
- Werving
- Fakultni Thomayerova nemocnice /ID# 269632
-
-
-
-
-
Manchester, Verenigd Koninkrijk, M20 4BX
- Werving
- The Christie NHS Foundation Trust - Christie Hospital /ID# 271561
-
-
Greater London
-
London, Greater London, Verenigd Koninkrijk, E1 2ES
- Werving
- Barts Health NHS Trust /ID# 271189
-
-
Oxfordshire
-
Oxford, Oxfordshire, Verenigd Koninkrijk, OX3 9DU
- Werving
- Oxford University Hospitals Nhs Foundation Trust /ID# 272486
-
-
Surrey
-
Sutton, Surrey, Verenigd Koninkrijk, SM2 5PT
- Werving
- The Royal Marsden - Sutton /ID# 271172
-
-
West Midlands
-
Birmingham, West Midlands, Verenigd Koninkrijk, B9 5SS
- Werving
- Heartlands Hospital - University Hospitals Birmingham /ID# 271178
-
-
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- Werving
- City of Hope National Medical Center /ID# 270255
-
Santa Monica, California, Verenigde Staten, 90404
- Werving
- UCLA - Santa Monica /ID# 270621
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06510
- Werving
- Yale New Haven Hospital /ID# 270565
-
-
Florida
-
Orlando, Florida, Verenigde Staten, 32803
- Werving
- AdventHealth Orlando /ID# 270789
-
-
Georgia
-
Marietta, Georgia, Verenigde Staten, 30060
- Werving
- Northwest Georgia Oncology Centers /ID# 270245
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- University of Chicago Medical Center /ID# 271688
-
Hinsdale, Illinois, Verenigde Staten, 60521
- Werving
- Hope And Healing Cancer Services /ID# 271562
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Werving
- Dana-Farber Cancer Institute /ID# 270624
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109-5000
- Werving
- University Of Michigan /ID# 270790
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64111
- Werving
- Saint Lukes Hospital of Kansas City /ID# 270633
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68130
- Werving
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27514
- Werving
- University of North Carolina at Chapel Hill /ID# 267786
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45245
- Werving
- Oncology Hematology Care - Eastgate /ID# 271493
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78705
- Werving
- Texas Oncology - Austin Midtown /ID# 271354
-
Webster, Texas, Verenigde Staten, 77598
- Werving
- Texas Oncology - Deke Slayton Cancer Center /ID# 271355
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Werving
- Virginia Cancer Specialists - Fairfax /ID# 271351
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98109
- Werving
- University Of Washington /ID# 271298
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Laboratory values meeting the criteria within the protocol.
- Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
Exclusion Criteria:
- Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
- History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Substudy 1: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Experimenteel: Substudy 1: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Experimenteel: Substudy 1: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecandetermined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Experimenteel: Substudy 1: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Experimenteel: Substudy 2: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil (5-FU) and leucovorin (LV) and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Experimenteel: Substudy 2: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Experimenteel: Substudy 2: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Experimenteel: Substudy 2: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and panitumumab as part of the approximately 6 year study duration. |
IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection IV Infusion |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1.
Tijdsspanne: Up to 24 Weeks
|
OR is defined as confirmed CR or PR as assessed by the investigator per RECIST, version 1.1. |
Up to 24 Weeks
|
|
Number of Participants with Adverse Events (AE)s
Tijdsspanne: Up to Approximately 6 Years
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 6 Years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-Free Survival (PFS) as Assessed by the Investigator
Tijdsspanne: Up to 22 Months
|
PFS is defined as the time from the first dose of study treatment to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by the investigator or death from any cause, whichever occurs earlier. |
Up to 22 Months
|
|
Duration of Response (DOR) as Assessed by the investigator
Tijdsspanne: Up to 14 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by the investigator or death from any cause, whichever occurs first. |
Up to 14 Months
|
|
Overall Survival (OS)
Tijdsspanne: Up to Approximately 6 Years
|
OS is defined as the time from first dose of study treatment to the event of death from any cause. |
Up to Approximately 6 Years
|
|
Disease Control (DC) as Assessed by the Investigator
Tijdsspanne: Up to Approximately 6 Years
|
DC is defined as best overall response of confirmed CR or confirmed PR, or stable disease (SD) based on RECIST, version 1.1 as determined by the investigator. |
Up to Approximately 6 Years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: ABBVIE INC., AbbVie
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Darmziekten
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Intestinale neoplasmata
- Rectale ziekten
- Colon Ziekten
- Colorectale neoplasmata
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Enzymen en co -enzymen
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Coördinatiecomplexen
- Pyrimidines
- Formyltetrahydrofolates
- Tetrahydrofolaten
- Foliumzuur
- Pterins
- Pteridines
- Uracil
- Pyrimidinonen
- Co -enzymen
- Oxaliplatine
- Bevacizumab
- Panitumumab
- Fluorouracil
- Leucovorin
Andere studie-ID-nummers
- M24-533
- EU CT (Andere identificatie: 2024-512981-33-00)
- 2024-512981-33-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-tijdsbestek voor delen
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD-toegangscriteria voor delen
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .